Patient co-payments for women diagnosed with breast cancer in Australia

Bates, Nicole; Callander, Emily; Lindsay, Daniel; Watt, Kerrianne

doi:10.1007/s00520-019-05037-z

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average out-of-pocket costs and number of MBS services and PBS prescriptions claimed were similar to a study looking at these factors over three years post diagnosis [ 17 ]. Of interest here is that the average cost to the individual, and average number of services claimed, remained steady over a five-year period after the initial six months post diagnosis.…”

Section: Discussionsupporting

confidence: 66%

“…A study by Gordon et al found that the median out-of-pocket costs for women with breast cancer was AU$4192 in the first two years post-diagnosis [ 16 ]. Another study indicated that average co-payments for MBS items in the first three years following a breast cancer diagnosis was AU$1400 (SD = $1946), while average co-payments for pharmaceuticals was $AU974 (SD = $707) in the same period [ 17 ]. While providing an indication of the out-of-pocket costs for breast cancer for Australian women, the long-term out-of-pocket costs (costs incurred over five or more years) resulting from a breast cancer diagnosis have yet not been fully explored.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantifying the Costs to Different Funders over Five-Years for Women Diagnosed with Breast Cancer in Queensland, Australia: A Data Linkage Study

Lindsay

Callander

2021

IJERPH

Self Cite

View full text Add to dashboard Cite

Individuals diagnosed with breast cancer have the highest rates of survival among all cancer types. Due to high survival, the costs of breast cancer to different healthcare funders are of interest. This study aimed to describe the cost to public hospital and private health funders and individuals due to hospital and emergency department (ED) admissions, as well Medicare items and pharmaceuticals over five years for Queensland women with breast cancer. We used a linked administrative dataset, CancerCostMod, limited to Queensland female breast cancer diagnoses between July 2011 and June 2013 aged 18 years or over who survived for 5 years (n = 5383). Each record was linked to Queensland Health Admitted Patient Data Collection, Emergency Department Information Systems, Medicare Benefits Schedule, and Pharmaceutical Benefits Scheme records between July 2011 and June 2018. Total costs for different healthcare funders as a result of breast cancer diagnoses were reported, with high costs and service use identified in the first six months following a breast cancer diagnosis. After the first six months post-diagnosis, the financial burdens incurred by different healthcare funders for breast cancer diagnoses in Queensland remain steady over a long period. Recommendations for reducing long term costs are discussed.

show abstract

Section: Discussionsupporting

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Quantifying the Costs to Different Funders over Five-Years for Women Diagnosed with Breast Cancer in Queensland, Australia: A Data Linkage Study

Lindsay

Callander

2021

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, [25] found that among 235,368 French patients diagnosed with early breast cancer between 2011 and 2017 (identified by the Oncology Data Platform -(ODP) of the French National Cancer Institute (INCa)), 95% were 40 years old or above at the time of diagnosis. [29] used the Queensland Cancer Registry and found that among 3,079 women diagnosed with breast cancer in Queensland (Australia) between July 1st 2011 and June 30th 2012, 87.9% were older than 45 years. Based on our findings and the above-mentioned reports from the literature, it could be assumed that most women diagnosed with breast cancer are over 40 years of age.…”

Section: Discussionmentioning

confidence: 99%

New Real Dataset Creation to Develop an Intelligent System for Predicting Chemotherapy Protocols

BRAHIM,

BENLLARCH,

BENHIMA

et al. 2023

IJACSA

View full text Add to dashboard Cite

Breast cancer is the most common cancer diagnosed in women. In developing countries, controlling this scourge is often problematic due to late diagnosis and the lack of medical and human resources. Automation and optimization of treatment is then needed to improve patient outcome. The use of medical datasets could, according to medical staff and pharmacists, assist them in clinical decision-making and would allow for better use of resources especially when limited. In our paper, a new real dataset was produced by collecting medical and personal data from 601 patients with breast cancer at the University Hospital Center (UHC) Mohammed VI of Marrakech. Data of women diagnosed with breast cancer from January 2018 at UHC were assessed. Most patients were 24-85 year-old, with an average age of 48.84 years. Patient age, performance status (PS), cancer stage and subtype, treatment patterns and correlations among the different variables were analyzed. The created dataset will help to determine the most appropriate treatment regimen depending on the individual characteristics of patients to allow for better use of limited resources.

show abstract

A cross-sectional analysis of out-of-pocket expenses for people living with a cancer in rural and outer metropolitan Western Australia

Slavova‐Azmanova¹,

Newton²,

Johnson

et al. 2021

Aust. Health Rev.

View full text Add to dashboard Cite

ObjectiveTo determine the extent of medical and non-medical out-of-pocket expenses (OOPE) among regional/rural and outer metropolitan Western Australian patients diagnosed with cancer, and the factors associated with higher costs. MethodsCross-sectional data were collected from adult patients living in four regional/rural areas and two outer metropolitan regions in Western Australia who had been diagnosed with breast, prostate, colorectal or lung cancer. Consenting participants were mailed demographic and financial questionnaires, and requested to report all OOPE related to their cancer treatment. ResultsThe median total OOPE reported by 308 regional/rural participants and 119 outer metropolitan participants were A$1518 (interquartile range (IQR): A$581–A$3769) and A$2855 (IQR: A$958–A$7142) respectively. Participants most likely to experience higher total OOPE were younger than 65 years of age, male, resided in the outer metropolitan area, worked prior to diagnosis, had private health insurance, were in a relationship, and underwent surgery. Multivariate analysis of regional/rural participants revealed that receiving care at a rural cancer centre was associated with significantly lower non-medical OOPE (estimated mean A$805, 95% confidence interval (CI): A$735–A$875, P=0.038; compared with other rural participants (A$1347, 95% CI: A$743–A$1951, P<0.001)). ConclusionThe cancer patients who participated in this study experienced variation in OOPE, with outer metropolitan participants reporting higher OOPE compared with their regional/rural counterparts. There is a need for cost transparency and access to care close to home, so that patients can make informed choices about where to receive their care. What is known about the topic?In recent years, OOPE for health care in general and cancer in particular have been widely debated by consumers and not-for-profit organisations; the topic has attracted much political attention because it affects both equity and access to care and has wider financial implications for the community. Research studies and reports from both consumer organisations and a Ministerial Advisory Committee found that cancer patients can face exorbitant out-of-pocket costs, and that individuals with private health insurance and those with prostate and breast cancer reported higher costs. In Western Australia, a cancer centre providing comprehensive cancer care was established in the second most populous region to ameliorate the high costs for travel and accommodation that regional cancer patients are known to experience. What does this paper add?This study is unique because it collected detailed cost information from patients and reports on the OOPE of regional/rural and outer metropolitan Western Australian patients receiving care for one of the four most common cancers; it therefore offers novel insight into the experiences of these groups. This study demonstrates that outer metropolitan cancer patients are experiencing much higher OOPE compared with regional/rural cancer patients. Additionally, regional/rural study participants who accessed a Regional Cancer Centre experienced significantly lower non-medical OOPE, compared with regional/rural study participants receiving care elsewhere. What are the implications for practitioners?First, there is a need for improved communication of OOPE to minimise costs to the patient, for example, by facilitating access to local cancer care. Health service providers and insurance companies can improve cost transparency for cancer patients by making this information more readily available, allowing patients to make informed financial choices about where to seek care. Second, the needs of working patients deserve specific attention. These patients face significant work uncertainty and additional distress following a cancer diagnosis.

show abstract

Patient co-payments for women diagnosed with breast cancer in Australia

Cited by 3 publications

References 12 publications

Quantifying the Costs to Different Funders over Five-Years for Women Diagnosed with Breast Cancer in Queensland, Australia: A Data Linkage Study

Quantifying the Costs to Different Funders over Five-Years for Women Diagnosed with Breast Cancer in Queensland, Australia: A Data Linkage Study

New Real Dataset Creation to Develop an Intelligent System for Predicting Chemotherapy Protocols

A cross-sectional analysis of out-of-pocket expenses for people living with a cancer in rural and outer metropolitan Western Australia

Contact Info

Product

Resources

About